PURPOSE: To evaluate the outcome of a prospective protocol for the treatment of @entity989 (CSC). METHODS: Interventional prospective case series in 59 eyes (59 @entity1 ) with active chronic CSC. All @entity1 were first treated with @entity3194 angiography (ICGA)-guided half-dose photodynamic therapy (PDT). In case of persistent serous @entity5173 ( @entity5173 ) after a follow-up period of at least 6  weeks, ICGA-guided PDT was repeated. If the @entity5173 persisted after two PDT treatments, additional ICGA-guided high-density subthreshold diode micropulse laser (HSML) therapy was performed. Clinical evaluation included best-corrected visual acuity (BCVA), fundoscopy, @entity6653 , fundus autofluorescence, @entity941 angiography and ICGA. RESULTS: After a single PDT treatment, complete resolution of @entity5173 was seen in 37 of 59 eyes. Of the 22 eyes with no complete resolution of @entity5173 , 19 eyes received a second PDT treatment, after which seven eyes of the 19 eyes showed a complete resolution of @entity5173 . Ten eyes underwent HSML, of which one eye had complete resolution of @entity5173 within 7  weeks. At final follow-up a complete resolution of @entity5173 was present in 80% of all eyes. The mean BCVA improved from 0.28 logMAR at baseline to 0.16 logMAR at final follow-up. Improvement of BCVA was highest after the first treatment (-0.12 logMAR, p  <  0.001). CONCLUSIONS: The proposed treatment strategy using half-dose PDT and HSML in active chronic CSC resulted in an anatomical success rate of 80%. The first half-dose PDT treatment has the highest likelihood of a favourable treatment response on @entity6653 and BCVA increase.

Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for XXXX : evaluation of a prospective treatment protocol.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity6653 :: ('5362', 'Gene') :: ['OCT'] @entity3194 :: ('MESH:D007208', 'Chemical') :: ['indocyanine green'] @entity5173 :: ('MESH:D065634', 'Disease') :: ['SRF', 'subretinal fluid'] @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein'] @entity989 :: ('MESH:D012164', 'Disease') :: ['chronic central serous chorioretinopathy']
@entity989 :: (MESH:D012164,Disease) :: ['chronic central serous chorioretinopathy']
